 |
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
|
TARIBAVIRIN and RETIGABINE are products in clinical development. None of them have been found to be safe or effective for the treatment of any disease or illness. They may not be sold or promoted in the United States unless and until they are approved by the FDA. Similar restrictions apply in other countries. _______________________________________________________________________________________________________________________ Valeant Pharmaceuticals International has established an anonymous Reporting Helpline by which any interested party may report concerns regarding potential fraud, unethical behaviors, noncompliance with the Code of Business Conduct and Ethics or other matters which the reporting party believes should be brought to the attention of the Company. The Reporting Helpline is monitored by MySafeWorkplace®, an independent company with staff that speaks the languages of all countries where we do business, which provides secure, anonymous incident reporting not affiliated with any religious or political group. The Reporting Helpline is available and can be reached in the United States and Canada at 1-800-461-9330, from other international locations by dialing collect at 1-720-514-4000, or via the internet at www.mysafeworkplace.com. |
|
